Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 756 across all filing types
Latest filing 2022-10-28 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
2022年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2022 Third Quarter Report" of 科兴生物制药股份有限公司, indicating it is a quarterly financial report. It contains detailed financial data, including main accounting data, financial indicators, non-recurring gains and losses, and shareholder information. The report explicitly states it is a quarterly report and includes substantive financial data and analysis for the quarter. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q3 2022
2022-10-28 Chinese
自愿披露关于获得人干扰素 α2b 喷雾剂药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (1000 characters) from a pharmaceutical company about receiving approval from the National Medical Products Administration for clinical trials of a new drug. It contains no financial statements or detailed financial data, nor does it present a report or detailed analysis. It is an official regulatory announcement about a clinical trial approval, which is a regulatory update rather than a financial or management report. The document is not a report itself but an announcement of a regulatory event. Therefore, it fits best under Regulatory Filings (RNS).
2022-10-28 Chinese
自愿披露关于收到聚乙二醇化人粒细胞刺激因子注射液药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 科兴生物制药股份有限公司 regarding the receipt of an official clinical trial approval notice from the National Medical Products Administration (国家药监局) for a new drug. It details the drug name, approval number, and the clinical trial approval conclusion. The document explicitly states that this approval will not have a significant immediate financial impact and discusses the potential future benefits and risks. The document length is short (1183 characters) and it is an announcement of a regulatory approval event rather than a financial report or detailed management discussion. There is no financial data, no earnings information, no management changes, no voting results, and no detailed report attached or referenced. This fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2022-10-16 Chinese
自愿披露关于收到人干扰素α2b泡腾胶囊药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a pharmaceutical company about receiving approval from the National Medical Products Administration for clinical trials of a new drug formulation. It contains no financial data, no management discussion, no earnings information, and no regulatory certifications. It is a regulatory announcement about a clinical trial approval, which is a general regulatory update rather than a financial or governance report. The document length is short (979 characters), and it is an announcement of an event rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS).
2022-10-16 Chinese
中信建投证券股份有限公司关于科兴生物制药股份有限公司2022年半年度持续督导跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2022年半年度持续督导跟踪报告" which translates to "2022 Semi-Annual Continuous Supervision Follow-up Report". It is issued by the sponsor institution 中信建投证券股份有限公司 for 科兴生物制药股份有限公司. The content includes detailed supervisory activities, risk factors, financial data for the first half of 2022, and compliance with regulatory requirements. The document contains substantive financial data and analysis for a half-year period, including income, profit, cash flow, and R&D expenses. It is not merely an announcement or a certification but a comprehensive report on the company's half-year performance and ongoing supervision. This matches the definition of an Interim / Quarterly Report (IR). H1 2022
2022-09-09 Chinese
关于召开2022年半年度业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling and details of a 2022 half-year performance explanation meeting (业绩说明会) for investors. It references the previously published 2022 half-year report but does not contain the report itself or detailed financial data. The document provides information on the meeting time, location, participation method, and contact details. It is essentially an invitation and informational notice about the upcoming investor presentation event rather than the presentation or report itself. Therefore, it fits best under the category of Investor Presentation (IP) as it focuses on the event where financial results and business performance will be discussed with investors.
2022-09-06 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.